Skip to content
Review Open access

Gut microbiota modulation of the gut-brain axis: Therapeutic implications in neurodegenerative and psychiatric disorders

Oct 2026 · International Health Sciences Review · 0 citations

Abstract

The gut microbiota communicates with the central nervous system through neural, immune, endocrine and metabolic pathways collectively termed the microbiota-gut-brain axis. Because the microbiota can be modified by diet, probiotics, prebiotics and faecal microbiota transplantation (FMT), this axis has become a candidate therapeutic target in brain disorders. This narrative review examines the experimental and clinical evidence linking the gut microbiota to neurodegenerative and psychiatric disorders and the results of interventions that modify it. Experimental studies show that microbiota-derived short-chain fatty acids regulate microglial maturation, that gut microbiota are required for motor deficits and α-synuclein pathology in a mouse model of Parkinson's disease, and that pathological α-synuclein injected into the gut reaches the brain through the vagus nerve, a spread prevented by vagotomy. In humans, more than 30% of microbial species, genes and pathways tested were altered in 490 patients with Parkinson's disease, the microbiome of patients with Alzheimer's disease showed reduced diversity and taxa that correlated with cerebrospinal fluid biomarkers, and a meta-analysis of 59 case-control studies found a transdiagnostic depletion of butyrate-producing bacteria in depression, bipolar disorder, schizophrenia and anxiety. Clinically, a single FMT improved the off-medication motor score by 5.8 points at 12 months in early Parkinson's disease, against 2.7 points with placebo; probiotics produced small effects on depression in a meta-analysis of 34 trials, larger in clinical samples; an adjunctive probiotic in depression with incomplete response to antidepressants showed promising effect sizes in a pilot trial; and microbiota transfer therapy in 18 children with autism and gastrointestinal symptoms was followed by a 47% reduction in autism severity at two years in an open-label study. Taken together, the evidence supports a causal role for the microbiota in experimental models and consistent associations in patients, while clinical efficacy remains preliminary, derived from small trials with short follow-up. Microbiota-based interventions should be regarded as investigational adjuncts rather than established treatments. Practical aspects of current strategies are also reviewed.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.